Although partial nephrectomy (PN) represents the recommended management for small renal masses, recent series have suggested an increased risk of postprocedural hypertension relative to radical nephrectomy (RN). Our objective was to investigate the risks of new-onset and worsened hypertension after RN versus PN.
INTRODUCTION AND OBJECTIVES:
Although partial nephrectomy (PN) represents the recommended management for small renal masses, recent series have suggested an increased risk of postprocedural hypertension relative to radical nephrectomy (RN). Our objective was to investigate the risks of new-onset and worsened hypertension after RN versus PN.
METHODS: Using a national administrative database of privately insured and Medicare patients. a retrospective cohort study was performed of 9,207 patients and 4,686 patients who underwent RN and PN, respectively, for a renal mass between 01/01/2007 and 12/31/2016. One-to-one propensity-score matching was used to balance surgical groups based on patient demographics, baseline comorbidities, current medications, and surgery year. Primary outcomes included new-onset hypertension among patients with no history of hypertension, and worsened hypertension among patients with baseline hypertension. Subgroup analyses were conducted, stratified by age (!75 versus <75 years) and presence of baseline kidney disease. Incidence rates and Cox proportional hazards models were used to compare outcomes in matched cohorts.
RESULTS: Among 3,106 propensity-matched patients without preexisting hypertension, RN was associated with a higher risk for new-onset hypertension compared to PN (HR[1.40, P<0.001) . Similarly, among 6,250 propensity-matched patients with hypertension prior to surgery, RN was associated with a higher risk for worsening of baseline hypertension (HR[1.18, 95%CI[1.10-1.26, P<0.001). Subgroup analyses were consistent with the main study findings for worsened hypertension (P for interaction !0.05).
CONCLUSIONS: Radical nephrectomy was associated with higher risk for new-onset and worsened hypertension compared to PN, including among elderly patients and individuals with normal kidney function. Given prior noted associations between hypertension and non-cancer related morbidity, our results further encourage the preferential use of PN for management of localized renal masses when technically feasible. This rare sub-variant is associated with extremely poor clinical outcomes. Due to its rarity, limited studies have evaluated the impact of sarcomatoid differentiation among patients, especially with lower stage pT1-2 disease. We herein report survival trends stage-for-stage between sRCC and non-sRCC patients who underwent nephrectomy.
METHODS: After IRB approval, we queried our prospectively maintained database for patients who underwent partial or radical nephrectomy between 2000-2017. Patients were divided into four groups for analysis: non-sRCC pT1-2; non-sRCC pT3-4; sRCC pT1-2 and sRCC pT3-4. All patients included were NxMx. Clinicopathological outcomes including sex, race, age, primary histology, lymph node involvement and margin status were compared between groups using chi-squared and two-tailed t-tests. Overall survival rates were analyzed by constructing Kaplan Meier curves, p-values were calculated using log rank tests and fitting Cox proportional hazards models for adjusted analyses.
RESULTS: In a total of 3,850 cases available for analysis, sRCC was identified in 168 (4.4%) patients. Mean overall follow-up for the entire cohort was 59.9 months (range 1-192). Lower stage (pT1-2) was present in 33 (19.6%) sRCC patients and in 2,644 (71.8%) nonsRCC patients. Cancer-Specific Survival (CCS) between groups was worse in patients with sarcomatoid features regardless of pT stage
